定制
滥用责任
医学
责任
药品
风险分析(工程)
业务
药理学
财务
广告
作者
Thulasi Ramani,Ronald L. Wange,T. Scott Manetz,Paul J. Kruzich,Susan Laffan,David M. Compton
标识
DOI:10.1177/10915818241259794
摘要
Nonclinical safety studies are typically conducted to establish a toxicity profile of a new pharmaceutical in clinical development. Such a profile may encompass multiple differing types of animal studies, or not! Some types of animal studies may not be warranted for a specific program or may only require a limited evaluation if scientifically justified. The goal of this course was to provide a practical perspective on regulatory writing of a dossier(s) using the weight of evidence (WOE) approach for carcinogenicity, drug abuse liability and pediatric safety assessments. These assessments are typically done after some clinical data are available and are highly bespoke to the pharmaceutical being developed. This manuscript will discuss key data elements to consider and strategy options with some case studies and examples. Additionally, US FDA experience with dossier(s) including WOE arguments is discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI